Revolution Medicines (NASDAQ:RVMD) COO Margaret Horn Sells 4,847 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 4,847 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $372,346.54. Following the completion of the sale, the chief operating officer owned 141,053 shares of the company’s stock, valued at approximately $10,835,691.46. This trade represents a 3.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Revolution Medicines Trading Down 1.0%

NASDAQ RVMD opened at $75.96 on Friday. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $81.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.05 and a current ratio of 8.05. The stock has a market cap of $14.68 billion, a price-to-earnings ratio of -14.69 and a beta of 0.96. The firm’s 50 day moving average price is $66.12 and its two-hundred day moving average price is $48.95.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same quarter in the prior year, the firm posted ($0.94) earnings per share. Equities analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Wall Street Analyst Weigh In

RVMD has been the subject of a number of research reports. Wedbush raised their price objective on Revolution Medicines from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Raymond James Financial raised their price target on shares of Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a report on Friday, October 17th. Needham & Company LLC boosted their price objective on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Royal Bank Of Canada initiated coverage on shares of Revolution Medicines in a research report on Monday, November 3rd. They issued an “outperform” rating and a $77.00 target price for the company. Finally, Stifel Nicolaus initiated coverage on shares of Revolution Medicines in a research note on Wednesday, October 15th. They set a “buy” rating and a $85.00 target price for the company. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of “Buy” and an average target price of $78.50.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RVMD. Farallon Capital Management LLC grew its position in Revolution Medicines by 2.1% in the third quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock worth $683,020,000 after acquiring an additional 300,000 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in shares of Revolution Medicines by 1.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock valued at $441,565,000 after purchasing an additional 90,385 shares in the last quarter. Nextech Invest Ltd. lifted its stake in shares of Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Paradigm Biocapital Advisors LP lifted its stake in shares of Revolution Medicines by 2.1% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,223,291 shares of the company’s stock valued at $290,628,000 after purchasing an additional 130,000 shares during the last quarter. Finally, Bellevue Group AG boosted its holdings in Revolution Medicines by 21.7% in the third quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock worth $260,298,000 after purchasing an additional 994,538 shares in the last quarter. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.